- Dec 31, 2020
HealthTree University Myeloma: What are the different catheters and ports?
HealthTree University Myeloma: What are the different catheters and ports? HealthTree University Myeloma: What are the different catheters and ports? HealthTree University Myeloma https://www.youtube.com/c/HealthTreeUniversity/videos
77
- Dec 31, 2020
Dana-Farber's 2020 Multiple Myeloma Patient Symposium - Current and Future Treatment of Myeloma
Watch on YouTube Current and Future Treatment of Multiple Myeloma Jan 19, 2021 Dana-Farber Cancer Institute https://www.dana-farber.org/multiple-myeloma-program/ https://www.dana-farber.org/health-library/videos/multiple-myeloma-patient-symposium-video-presentations/
66
- Dec 30, 2020
NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM
NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients This is a single arm, open-label, multicenter phase I study to assess the safety, tolerability and preliminary efficacy of autologous T cells transduced with a specific γδTCR, i.e. TEG002, in a dose escalation and expansion study in relapsed/refractory Multiple Myeloma patients. Sponsor Gadeta B.V. ClinicalTrials.gov Identifier: NCT04688853 Offi
194
- Dec 29, 2020
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma Relapsed & Refractory Multiple Myeloma The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3). TALMMY1001-Part 3 The corresponding study (NCT03399799) is the Phase 1
748
- Dec 27, 2020
NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma
A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open label, study of CC-95266 in subjects with relapsed and/or refractory multiple myeloma. The study will consist of two parts: dose escalation (Part A) and dose expansion (Part B).
The dose escalation (Part A) of the study will evaluate the safety and tolerability of increasing doses of CC-95266 in a single administration to establish a maximum tolerated do
263
- Dec 24, 2020
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
NCT04570631: Phase 1: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Ch
76
- Dec 23, 2020
NCT04582539: Phase 1/2: Safety and Tolerability of INCB000928 in Myelodysplastic Synd. or Myeloma
NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma. NCT04582539: Phase 1/2: To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma. This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or M
42
- Dec 23, 2020
NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance
Phase 2 - Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma NCT04680468: Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma
190
- Dec 19, 2020
Myeloma Canada: Patient Handbook - MGUS and Smoldering Multiple Myeloma
Myeloma Canada: Patient Handbook - MGUS and Smoldering Multiple Myeloma https://myeloma.ca/pixms/uploads/serve/ckeditor/mgus_and_smm_infoguide_en_final_web.pdf Learn more: https://myeloma.ca/en/resources/myeloma-canada-patient-and-caregiver-educational-publications www.myeloma.ca
105
- Dec 19, 2020
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies. Sponsor Compugen Ltd ClinicalTrials.gov Identifier: NCT04354246 Official Title: A Phas
57
- Dec 19, 2020
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS RRMM Myeloma
NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide (R) and dexamethasone (d) in pati
63
- Dec 18, 2020
NCT04458831: A Non-interventional, Multinational, Observational study With Isatuximab in RRMM
IONA-MM NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM) NCT04458831: A Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM) To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 mo
24
- Dec 18, 2020
FDA Approved for RRMM: Xpovio (selinexor) tablets + Velcade (Bortezomib) and Dexamethasone
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. FDA granted selinexor accelerated approval in 2019 in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who received at least four prior therapie
170
- Dec 18, 2020
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With RRMM
NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma NCT04635735: Phase 1/2: Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received chemotherapy and allogeneic hema
75
- Dec 17, 2020
NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM
NCT04634435: Phase 1/2: Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients Newly diagnosed Multiple Myeloma NDMM Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytoki
185
- Dec 17, 2020
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
MCARH109
CART MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment. The study treatment could stop the growth of the cancer, but it could also cause side effects. Sponsor Memorial Sloan Kettering Cancer Center ClinicalTrials.gov Identifier: NCT04555551
574
- Dec 17, 2020
CAR T-Cell Therapy: ASCO’s 2018 Advance of the Year
CAR T-Cell Therapy: ASCO’s 2018 Advance of the Year Learn more: https://www.cancer.net https://www.cancer.net/research-and-advocacy/clinical-trials/welcome-pre-act
70
- Dec 17, 2020
NCT04497961: Phase 2: A Study of Health-Related Quality of Life with Daratumumab or Lenalidomide
NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare givi
67
- Dec 15, 2020
NCT04505813: Phase 1- Antigen-specific T Cell Therapy NEXI 002 Relapsed Refractory Multiple Myeloma
NCT04505813: Phase 1- Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-002 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting multiple Myeloma associated antigen peptides in patients with relapsed refractory multiple myeloma (MM). The study will enroll patients with
175